Holen Sie sich die Stockscreener-App
71.63
7.41%
-5.73
Handel nachbörslich:
70.57
-1.06
-1.48%
Soleno Therapeutics Inc Aktie (SLNO) Neueste Nachrichten
Soleno Therapeutics Stock Slumps After Scorpion Capital Reveals Short Position: But Retail’s Not Pessimistic Yet - Stocktwits
Soleno Under Serious Scrutiny As Short Seller Alleges PWS Drug Is Overpriced, Unsafe - Benzinga
Scorpion Capital discloses short position in drugmaker Soleno - whbl.com
Soleno Therapeutics stock falls after Scorpion Capital short report By Investing.com - Investing.com Nigeria
Soleno Therapeutics stock falls after Scorpion Capital short report - Investing.com
Soleno Therapeutics Plunges 10.81% Amid Investor Sentiment Shift - AInvest
Soleno Therapeutics plunges after short report from Scorpion Capital (SLNO:NASDAQ) - Seeking Alpha
Scorpion Capital shorts drug developer Soleno - TradingView
Scorpion Capital says we are short Soleno Therapeutics - MarketScreener
Is Soleno Therapeutics Inc. Starting a New UptrendWeekly Market Outlook & Weekly Top Performers Watchlists - newsyoung.net
What is Soleno Therapeutics Inc.’s market positionChart Signals & Capital Efficient Trade Techniques - sundaytimes.kr
Soleno (SLNO) Q2 Revenue Jumps 30% - AOL.com
What is the long term forecast for Soleno Therapeutics Inc. stockInsider Accumulation Tracker - thegnnews.com
Soleno Therapeutics Inc. Chart Enters High Volatility ZoneAI Driven Buy Alert Trade Blueprint Released - metal.it
Soleno Therapeutics: Analysts Predict 43.2% Upside Potential - AInvest
How Much Upside is Left in Soleno Therapeutics (SLNO)? Wall Street Analysts Think 43.15% - Yahoo Finance
Here's Why Momentum in Soleno Therapeutics (SLNO) Should Keep going - Yahoo Finance
Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports Second Quarter 2025 Financial Results - ADVFN Brasil
Regression Model Predicts Rangebound Movement in Soleno Therapeutics Inc.High Growth Low Risk Stock Selection Gets Analyst Nod - metal.it
Soleno signals $500M cash war chest and robust Vykat XR launch trajectory while advancing EU expansion - MSN
Soleno Therapeutics Posts Strong Q2 Earnings, Expects Continued Growth Despite Challenges. - AInvest
A Quick Look at Today's Ratings for Soleno Therapeutics(SLNO.US), With a Forecast Between $110 to $145 - 富途牛牛
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Q2 2025 Earnings Call Transcript - Insider Monkey
Soleno Therapeutics’ Earnings Call Highlights Success and Optimism - TipRanks
Soleno Therapeutics Receives Bullish Rating from Guggenheim, Price Target Raised to $106.00 - AInvest
Stifel raises Soleno Therapeutics stock price target to $118 on strong launch - Investing.com
Soleno Therapeutics price target raised to $120 from $115 at TD Cowen - TipRanks
Guggenheim raises Soleno Therapeutics stock price target to $106 on strong sales By Investing.com - Investing.com South Africa
Guggenheim raises Soleno Therapeutics stock price target to $106 on strong sales - Investing.com Australia
Earnings call transcript: Soleno Therapeutics beats Q2 2025 forecasts with strong revenue - Investing.com
Soleno Therapeutics Q2 2025: Key Contradictions in Time to Fill and Revenue Growth Expectations - AInvest
Soleno Therapeutics Reports Strong Q2 2025 Performance - TipRanks
Soleno Therapeutics Q2 2025 Earnings Call Transcript - MarketBeat
Transcript : Soleno Therapeutics, Inc., Q2 2025 Earnings Call, Aug 06, 2025 - MarketScreener
Strong Buy Recommendation for Soleno Therapeutics Driven by Impressive Vykat XR Launch and Market Demand - TipRanks
Soleno (SLNO) Q2 Revenue Jumps 30% - The Motley Fool
SOLENO THERAPEUTICS INC SEC 10-Q Report - TradingView
Soleno Therapeutics, Inc. (SLNO) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Soleno Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Soleno Therapeutics earnings beat by $0.55, revenue topped estimates - Investing.com Canada
Soleno reports $32.7 million in Q2 revenue from VYKAT XR launch By Investing.com - Investing.com South Africa
Soleno reports $32.7 million in Q2 revenue from VYKAT XR launch - Investing.com Nigeria
Soleno Therapeutics Q2 2025 Financial Results and VYKAT XR Launch Update - TradingView
Soleno Therapeutics Q2 net loss $4.7 mln - MarketScreener
Soleno Therapeutics Provides Update on U.S. Launch of - GlobeNewswire
Earnings Flash (SLNO) Soleno Therapeutics, Inc. Reports Q2 Revenue $32.7M, vs. FactSet Est of $25.1M - MarketScreener
Soleno Therapeutics Reports Q2 2025 Financial Results, Updates on VYKAT XR Launch - AInvest
Soleno Reports First Revenue Quarter: VYKAT XR Launch Draws 295 Prescribers in 90 Days - Stock Titan
When Will Soleno Therapeutics, Inc. (NASDAQ:SLNO) Become Profitable? - 富途牛牛
Is Soleno Therapeutics Inc. a growth stock or a value stockDiscover undervalued opportunities early - Jammu Links News
When is Soleno Therapeutics Inc. stock expected to show significant growthDynamic investment opportunities - Jammu Links News
Is Soleno Therapeutics Inc. a good long term investmentCapitalize on market trends before they peak - Jammu Links News
What makes Soleno Therapeutics Inc. stock price move sharplyHigh-impact investment strategies - Jammu Links News
What are analysts’ price targets for Soleno Therapeutics Inc. in the next 12 monthsUnmatched market gains - Jammu Links News
How does Soleno Therapeutics Inc. compare to its industry peersRealize exceptional returns through smart trading - Jammu Links News
What is the risk reward ratio of investing in Soleno Therapeutics Inc. stockCapitalize on momentum-driven investment opportunities - Jammu Links News
Should I hold or sell Soleno Therapeutics Inc. stock in 2025Maximize gains with proven stock analysis - Jammu Links News
What are the latest earnings results for Soleno Therapeutics Inc.Unlock powerful portfolio management tools - Jammu Links News
How does Soleno Therapeutics Inc. generate profit in a changing economyExplosive trading growth - Jammu Links News
Soleno Therapeutics Inc. Stock Analysis and ForecastMaximize returns with expert trading insights - Jammu Links News
0.41%
0.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):